ethyl 2-((1r,4r)-4-aminocyclohexyl)acetate hydrochloride | 76308-26-4

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: ethyl 2-((1r,4r)-4-aminocyclohexyl)acetate hydrochloride
• CAS: 76308-26-4
• 化学式: C₁₀H₁₉NO₂*ClH
• 分子量: 221.727
• InChiKey: KBMWRCPPPDEVSJ-JUAUBFSOSA-N

物化性质

• 熔点：
  177 °C
• 溶解度：
  少许溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.88
• 重原子数：
  14.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.32
• 氢给体数：
  1.0
• 氢受体数：
  3.0

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  ethyl 2-((1r,4r)-4-aminocyclohexyl)acetate hydrochloride 在 盐酸 、 sodium tetrahydroborate 、 lithium hydroxide monohydrate 、 三氟化硼乙醚 、 水 、 三乙胺 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 异丙醇 、 丙酮 为溶剂， 反应 43.0h， 生成 trans-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexylamine dihydrochloride
  参考文献：
  名称：

  一种卡利拉嗪及其中间体的制备方法

  摘要：

  本发明提供了一种卡利拉嗪及其中间体的制备方法。本发明公开了一种卡利拉嗪中间体5的制备方法，包括以下步骤：a)溶剂中，碱存在下，将2‑[1‑(4‑氨基]‑环己基)‑乙酸乙酯盐酸盐1与氨基保护试剂进行缩合反应，得到卡利拉嗪中间体2；b)在溶剂中，将卡利拉嗪中间体2，在碱性条件水解，然后酸化，得到卡利拉嗪中间体3；c)有机溶剂中，催化剂和碱存在下，将卡利拉嗪中间体3与1‑(2,3‑二氯苯基)‑哌嗪4进行缩合反应得到卡利拉嗪中间体5。本发明的制备方法原料易得，操作简便，反应收率高，适合于工业化生产。

  公开号：

  CN114539185A
• 作为产物：
  描述：

  对硝基苯乙酸乙酯 在 镍 盐酸 、 sodium hydroxide 、 氢气 作用下， 20.0~130.0 ℃ 、17.29 MPa 条件下， 反应 66.5h， 生成 ethyl 2-((1r,4r)-4-aminocyclohexyl)acetate hydrochloride
  参考文献：
  名称：

  Aminopyrimidines with High Affinity for Both Serotonin and Dopamine Receptors

  摘要：

  A series of {4-[2-(4-arylpiperazin-1-yl)alkyl]cyclohexyl}pyrimidin-2-ylamines was prepared and found to have receptor binding affinity for D2 and D3 dopamine (DA) receptors and serotonin 5-HT1A receptors. The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. From these studies compounds 14, 39, 42, 43, having potent affinity for both DA D2 and 5-HT1A receptors, were evaluated for intrinsic activity at these receptors, in vitro and in vivo. Compound 14 (PD 158771) had a profile indicative of partial agonist activity at both D2 and 5-HT1A receptors causing partially decreased synthesis of the neurotransmitters DA and 5-HT and their metabolites. This compound has a profile in behavioral tests that is predictive of antipsychotic activity, suggesting that mixed, partial agonists such as 14 may have utility as antipsychotic agents with increased efficacy and decreased side effects.

  DOI：

  10.1021/jm9707378

文献信息

• [EN] NEW BENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010043513A1

  公开（公告）日：2010-04-22

  The invention is concerned with novel benzimidazole derivatives of formula (I) wherein R1 to R6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds can be used as medicaments.

  这项发明涉及式(I)的新型苯并咪唑衍生物，其中R1至R6如描述和索赔中所定义，以及其生理上可接受的盐和酯。这些化合物可用作药物。
• [EN] IRAK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION D'IRAK ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020264499A1

  公开（公告）日：2020-12-30

  The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。这些化合物包括能够结合到IRAK4的IRAK结合基团和诱导降解的基团（DIM）。DIM可以是DTM、一个连接酶结合基团（LBM）或赖氨酸类似物。这些化合物可以作为IRAK蛋白激酶抑制剂，并应用于IRAK介导的疾病。
• CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES
  申请人：Benson Gregory Martin

  公开号：US20090163552A1

  公开（公告）日：2009-06-25

  This invention relates to novel carboxyl- or hydroxyl-substituted benzimidazole derivatives of formula (I) wherein R 1 to R 6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to FXR and can be used as medicaments.

  这项发明涉及公式（I）中的新型羧基或羟基取代苯并咪唑衍生物， 其中R1至R6如描述和索赔中所定义，以及其生理上可接受的盐和酯。这些化合物与FXR结合，可用作药物。
• TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS
  申请人：Incyte Corporation

  公开号：US20140121198A1

  公开（公告）日：2014-05-01

  The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

  本发明提供了三环融合噻吩衍生物，以及它们的组合物和使用方法，这些衍生物调节Janus激酶（JAK）的活性，并且在治疗与JAK活性相关的疾病方面具有用处，例如炎症性疾病、自身免疫性疾病、癌症和其他疾病。
• BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS
  申请人：Gobbi Luca

  公开号：US20090042943A1

  公开（公告）日：2009-02-12

  The present invention relates to compounds of formula (I) wherein R 1 and A are as defined in the specification as dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general formula (I) have high affinity for the dopamine D 3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT 2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.

  本发明涉及以下式（I）的化合物 其中R 1 和A如说明书中定义的作为血清素5-HT 2a 和多巴胺D 3 受体的双调节剂，它们的制备，含有它们的药物组合物以及它们作为药物的用途。一般式（I）的化合物对多巴胺D 3 和血清素（5-羟色胺；5-HT）5-HT 2A 受体具有高亲和力，并且在治疗精神分裂症等疾病以及抑郁症、焦虑症、药物依赖、痴呆症和记忆障碍等其他疾病中具有有效性。